News

Mitsubishi Buys Israel's NeuroDerm for $1.1B

(July 24, 2017) - Japan's Mitsubishi Tanabe Pharma has boosted its pipeline with a $1.1B deal to buy NeuroDerm, an Israeli developer of central nervous system therapies. The will see NeuroDerm merged with Mitsubishi's Israeli unit to become a wholly-owned subsidiary focusing on the development of a series of drug-device combinations for Parkinson's disease headed by phase III candidate ND0612. Read more…